Search Results for: Eight Factor Analysis

Assessing Abuse Potential of Cannabinoids: Lessons Learned from Past CNS-Active Drug Development

Jack Henningfield, Reginald Fant and Daniel Wang The confusing and conflicting legal status of cannabis and its active constituents can inhibit product development as companies encounter significant and unique barriers to approval and appropriate scheduling. In a complementary webinar, Jack Henningfield, Ph.D., and Daniel Wang described how the development and regulatory submission of other CNS-active... Read more »... Read More >

PinneyAssociates’ Abuse Potential Assessment of Natural Supplement Kratom Finds Evidence of Public Health Benefit and Little Harm

Kratom leaf-based products, from a South East Asian tree in the coffee family, are marketed as dietary supplements and often consumed in home brewed tea-like beverages or commercial products. Several million Americans consume kratom annually to increase alertness, enhance wellbeing and occupational performance. Kratom is also used as a natural remedy for several types of... Read more »... Read More >

Medicinal Cannabis: Lessons for Scheduling and FDA’s Expectations for Respiratory Drug Delivery

Development of cannabinoid-based medicines is a rapidly growing area of interest for patients with unmet needs as well as the pharmaceutical industry. The path forward, however, is fraught with technical and regulatory issues that require a thoughtful approach early and throughout the development process. At two recent medicinal cannabinoid conferences, CannMed 2017 and the 2017... Read more »... Read More >